MCAS Protocol Stack: VIP (10mg) / ARA-290 (2mg) / KPV (10mg) / TA-1 (5mg)

Regulatory Notice (July 2026): This stack contains KPV. On July 23, 2026, the FDA PCAC voted to recommend KPV for inclusion on the 503A Bulk Drug Substances List. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal rulemaking (12–24 months) must conclude first. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Europol Operation SHIELD VI (February 2026): Between April and November 2025, Europol coordinated Operation SHIELD VI — an international pharmaceutical crime enforcement operation across 30 countries resulting in 3,354 individuals prosecuted and €33 million (approx. $38.6M) in counterfeit medicines and illegal supplements seized, including peptides, doping agents, and anabolic compounds. Results announced February 25, 2026. This operation reinforces that cross-border sale of unregulated injectable compounds, including research peptides, is subject to active multi-jurisdictional enforcement. Sources: Europol press release (europol.europa.eu, February 25, 2026); OLAF; InsideTheGames (February 2026). INTERPOL Operation Pangea XVIII (March–May 2026): Between March 10 and 23, 2026, INTERPOL coordinated Operation Pangea XVIII across 90 countries and territories, targeting illicit pharmaceutical supply chains including online sellers of falsified medicines and unapproved injectables. In the UK alone, over two million doses of illicit medicines valued at £4.6 million were seized at the border. The Danish Medicines Agency reported six websites to police and detained 19 consignments. This operation specifically targeted online and social-media-driven sales of unapproved injectable products. Source: UK Government/MHRA (gov.uk, May 2026); Danish Medicines Agency (laegemiddelstyrelsen.dk, 2026); INTERPOL. Swissmedic / Basel-Landschaft Pratteln Seizure (October 7, 2026): On October 7, 2026, the Basel-Landschaft public prosecutor's office announced a criminal investigation after a September 2026 house search in Pratteln, Switzerland, seized more than 3,200 injection vials of illegally imported peptides plus syringes, packaging materials, and labels — described as the largest seizure of illegally imported peptides in Switzerland to date. Two individuals are under investigation for alleged violations of the Sport Promotion Act and the Therapeutic Products Act; the presumption of innocence applies. The case is linked to the June 22, 2026 cross-agency “Peptides 2026” campaign by Swissmedic, the Federal Office for Customs and Border Security (BAZG/FOCBS), and Swiss Sport Integrity (SSI), which inspected 46 packages of dubious peptide preparations (23 retained). Swiss authorities state that import of and trade in such unapproved injectable peptides is prohibited. Specific active ingredients in the Pratteln vials were not publicly named. This is Swiss domestic enforcement and does not change U.S. 503A/503B compounding status or FDA approval status of research peptides. Sources: Basel-Landschaft Staatsanwaltschaft media release (baselland.ch, 7 October 2026); Swiss federal press release on Peptides 2026 campaign (admin.ch, 30 June 2026); Swissinfo/Keystone-SDA (7 October 2026). HHS/FDA Interim Access Policy — OMB Review (October 14, 2026): On October 14, 2026, the U.S. Department of Health and Human Services and the Food and Drug Administration submitted an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for regulatory review (RIN 0910-ZD94; received October 14, 2026). The full text has not been published. News reports and industry analysis indicate the draft may outline enforcement-discretion conditions under which some licensed pharmacies could compound certain peptides while formal 503A Bulks List rulemaking proceeds after the July 2026 PCAC recommendations. This submission does not add any peptide to the 503A Bulks List, does not authorize compounding by itself, and is not a final rule. Until OMB clears the document and FDA publishes operative guidance or a rule, legal compounding status remains unchanged: PCAC recommendations are advisory only and notice-and-comment rulemaking has not concluded. Sources: POLITICO Prescription Pulse (October 16, 2026); Holland & Knight alert (October 2026); OMB/reginfo.gov regulatory review dashboard (RIN 0910-ZD94). Regulatory Notice (October 28–30, 2026 — HHS 503A ENFORCEMENT DISCRETION): This product contains KPV, which appear(s) on HHS Appendix A of the Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192; Docket HHS-OASH-2026-0496). Under the interim policy, HHS does not intend to take enforcement action against qualifying 503A state-licensed pharmacies, federal facilities, or licensed physicians compounding listed peptide bulk drug substances when all policy conditions are met. This is not FDA approval and does not place these substances on the final 503A bulks list; 503B outsourcing facilities are outside the stated scope. Sources: https://www.federalregister.gov/d/2026-22192 ; https://public-inspection.federalregister.gov/2026-22192.pdf ANSM (France, July 2026) previously published peptide-related safety communications; national rules outside the U.S. are unchanged by the HHS policy. FDA Interim Access Policy — OIRA Review (October 14, 2026): On October 14, 2026, HHS/FDA submitted an action titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) to the White House Office of Information and Regulatory Affairs (OIRA) for review under Executive Order 12866. The submission is listed as a Notice (not a proposed or final rule), not economically significant, with no legal deadline. As of October 23, 2026 the review remained pending and the full text had not been published; the public OIRA record does not name which peptides are covered. Press reporting (Associated Press/Reuters, citing unnamed sources) has described the intended approach as temporary enforcement discretion that could allow state-licensed 503A pharmacies to compound certain popular peptides — including BPC-157 — while longer-form 503A Bulks List rulemaking proceeds; that reporting is not an official FDA statement of covered substances or conditions. Stakeholder meetings with OIRA were scheduled for the week of October 21–28, 2026 (Alliance for Pharmacy Compounding, American Academy of Peptide Medicine, Hims & Hers Health, and others). This filing does not authorize compounding, does not add any substance to the 503A or 503B Bulks Lists, does not constitute FDA approval of any peptide, and does not change the research-use-only grey-market pathway. Formal notice-and-comment rulemaking remains required before any permanent 503A listing. Sources: OIRA EO 12866 dashboard (RIN 0910-ZD94, received Oct 14, 2026); POLITICO Prescription Pulse (Oct 16, 2026); Reuters (Oct 15, 2026); Holland & Knight (Oct 16, 2026); Alliance for Pharmacy Compounding (Oct 19, 2026). Partnership for Safe Medicines Citizen Petition (October 16–21, 2026): The Partnership for Safe Medicines (PSM) filed a citizen petition with the FDA asking the agency to refrain from allowing compounding of seven peptide bulk drug substances considered at the July 2026 PCAC meeting — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and epitalon — whether by regulation, Category 1 interim-policy placement, or enforcement discretion. The petition asks FDA to set aside the July PCAC recommendations, citing alleged Federal Advisory Committee Act and Ethics in Government Act conflicts and arguing that FDA staff briefing documents found inadequate characterization and insufficient human safety data. A citizen petition is a formal request for agency action; it is not itself a rule, ban, or final decision and does not change current 503A/503B status. It is part of the contested record surrounding any near-term interim access or bulks-list rulemaking. Sources: PSM press release and petition pages (safemedicines.org, October 21, 2026); AP News Business Wire (October 21, 2026).